Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...
Eli Lilly and Co (LLY) reports a 45% increase in Q4 revenue, driven by new products, while outlining ambitious growth and ...
Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.
Read a preview of Eli Lilly below and check back for more analysis soon. Investors already know what to expect when Eli Lilly ...
Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...
Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback